Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD209 in Patients With Cachexia and Advanced Malignancy
NCT00895726Phase 2Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Mar 2009
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of propranolol and etodolac in cancer-related cachexia, sponsored by Acacia Pharma Group Plc. Primary endpoint: Muscle size and function at 8 weeks. Started Mar 2009; status: completed.
02
Drugs
propranololetodolac
03
Conditions
cancer-related cachexia
Beyond the preview
Go deeper on NCT00895726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895726.